Skip to main content
TipRanks
Go Ultimate75% OFF

Revive Therapeutics (RVV) AI Stock Analysis

132 Followers
TSE:RVV

Revive Therapeutics

(CNQX:RVV)

Select Model
Rating:39Underperform
Price Target:CAD 0.01â–¼(-6.67% Downside)
Action:downgraded
Date:11/01/26

The score is driven primarily by severely distressed financials, including no revenue, negative equity, ongoing losses, and cash burn. Bearish technical positioning and the absence of meaningful valuation support reinforce the very high-risk profile.

Positive Factors
Low Debt BurdenVery low debt, including reported zero debt in 2026, reduces near-term refinancing pressure and interest obligations. This gives Revive some financial flexibility while it advances its development programs, although the benefit is limited by its negative equity and lack of operating revenue.
Negative Factors
No Commercial RevenueThe absence of revenue shows that Revive remains in a development-stage business model without commercial sales supporting operations. This leaves future financial performance dependent on successful drug development, regulatory progress, and eventual market adoption of its candidates.

Revive Therapeutics (RVV) vs. iShares MSCI Canada ETF (EWC)

-100%0%100%200%300%400%500%600%TSE:RVV+50.00%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 4.45M
Dividend Yield
―
Average Volume (3M)
154.00K
Price to Earnings (P/E)
-12.5
Beta (1Y)
-2.06
Revenue Growth
―
EPS Growth
90.84%
Country
Canada
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Revive Therapeutics Business Overview & Revenue Model

Company Description

Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory...

Revive Therapeutics Financial Statement Overview

Summary

Highly distressed financial profile: zero revenue, persistent operating and net losses, deeply negative equity, and continued negative operating and free cash flow. Debt elimination and reduced losses provide limited offset.

Income Statement

1Very Negative

Balance Sheet

4Very Negative

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Sep 2025Sep 2024Sep 2023Sep 2022
Income Statement
Total Revenue000000
Gross Profit-189-189-248-328-434-578
EBITDA-1.05M-1.05M-11.01M-5.60M-5.52M-17.74M
Net Income-1.02M-1.02M-11.01M-5.62M-6.32M-17.83M
Balance Sheet
Total Assets283.38K283.38K205.02K10.64M14.25M17.07M
Cash, Cash Equivalents and Short-Term Investments14.83K14.83K24.56K773.07K2.09M3.92M
Total Debt0066.87K25.22K219.69K327.73K
Total Liabilities4.30M4.30M3.66M3.40M3.60M4.46M
Stockholders Equity-4.02M-4.02M-3.46M7.23M10.65M12.60M
Cash Flow
Free Cash Flow-158.53K-158.53K-807.66K-3.29M-6.03M-13.06M
Operating Cash Flow-158.53K-158.53K-807.66K-3.29M-6.03M-13.06M
Investing Cash Flow00-30.00K000
Financing Cash Flow148.80K148.80K39.15K1.98M4.20M376.35K

Revive Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.01

Price Trends

50DMA0.02Negative
100DMA0.02Negative
200DMA0.03Negative

Market Momentum

MACD-0.00Negative
RSI47.69Neutral
STOCH100.00Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVV, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 47.69 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RVV.

Revive Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:RVV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:RAMMTSE:RAMM42NeutralCAD 1.79M-0.20-194.41%―-66.40%31.38%
TSE:PCLOTSE:PCLO39UnderperformCAD 9.34M-2.6728.59%―0.90%57.73%
TSE:RVVTSE:RVV39UnderperformCAD 6.67M-12.5026.78%――90.84%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%TSE:RVVTSE:PCLOTSE:RAMMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:RVV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:RVVRevive Therapeutics0.010.0050.00%
TSE:PCLOPharmacielo0.040.000.00%
TSE:RAMMRamm Pharma Corp0.01-0.04-75.00%

Revive Therapeutics Corporate Events

Business Operations and Strategy

Revive Therapeutics Moves to Build Global Bucillamine Franchise in Biodefence and Rare Diseases

Positive
Sep 16, 2026

Revive Therapeutics outlined a strategy to transform bucillamine into a globally protected therapeutic franchise spanning medical countermeasures, orphan diseases and government preparedness programs. The plan focuses on strengthening patent protecti...

Business Operations and StrategyPrivate Placements and Financing

Revive Therapeutics Moves to Settle Trade Debt Through Share Issuance

Neutral
Aug 19, 2026

Revive Therapeutics has proposed a shares-for-debt settlement under which it plans to issue up to 1,221,516 common shares at a deemed price of $0.05 to extinguish $61,061 in outstanding trade payables owed to two arm’s length creditors. The transacti...

Business Operations and Strategy

Revive Therapeutics Sets Bucillamine-Led Strategy for Biodefence and Pandemic Countermeasures

Positive
Aug 19, 2026

Revive Therapeutics has outlined a strategy to build a focused portfolio of medical countermeasures for biodefence and pandemic preparedness, anchored by its drug candidate bucillamine. The plan aims to serve government and public-health buyers who r...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 01, 2026